How does the SelectMDx test work?
SelectMDx for prostate cancer is a non-invasive urine test. It measures the amount of two genes that are associated with aggressive prostate cancer in urine. This is combined with clinical information to assess a man’s risk of having aggressive prostate cancer.
The SelectMDx test provides more information if one is concerned about his risk for prostate cancer. It allows for discrimination between prostate cancer and ‘benign’ prostate conditions such as prostatitis and an enlargement of the prostate (benign prostatic hyperplasia (BPH), adenoma). On top of that, the SelectMDx test can also discriminate aggressive prostate cancer from insignificant disease.
In clinical practice, the physician performs a digital rectal examination (DRE), as part of the normal diagnostic work-up: the physician gently inserts a gloved, lubricated finger into the rectum. After this exam, the patient is asked to urinate in a special device to collect the urine sample.
The sample is sent to the lab for analysis. After about 7 days the physician receives the report. This report indicates the patient’s probability of having prostate cancer, and most importantly, aggressive prostate cancer, according to the SelectMDx test.
Read more about the available options in case of an elevated PSA.